The myelodysplastic syndromes (MDS) are heterogeneous group of clonal disorders of hematopoietic stem cells, which manifestation is cytopenia and hypercellular, dysplastic bone marrow, often with increased amount of blasts. The pathogenesis of majority of MDS remains unexplained. It is regarded that genetic predisposition and exposure to toxic environmental agents contribute to genetic mutations in MDS. Molecular abnormalities have attracted interest over past years because of their presence in most cases of MDS, even without noticeable disorders in kariotype. Familial incidence of myelodysplastic syndromes may be helpful in understanding genetic factors of the disease. We describe two families in which MDS occurred in siblings (3 brothers; sister and brother). Kariotype abnormalities have been noted only in one person of each family. The rest of patients had a normal kariotype. This suggests that molecular abnormalities are the cause of their disease. The occupational exposure to precise mutagens (aluminium, greases, diesels, petrol, metals) was noted in two persons in the first family and correspondingly in one person in the second. There was absence of one mutagen common for every member of two reported families.
Download full-text PDF |
Source |
---|
Clin Lymphoma Myeloma Leuk
January 2025
Divisions of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan; Department of Laboratory Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Background: Myelodysplastic syndromes/neoplasms (MDS) are a diverse group of clonal myeloid disorders. Advances in molecular technology lead to the development of new classification systems. However, large-scale epidemiological studies on MDS in Asian countries are currently scarce.
View Article and Find Full Text PDFHemasphere
January 2025
Université Paris Cité, Institut Cochin, INSERM U1016, CNRS UMR8104 Assistance Publique-Hôpitaux de Paris.Centre, Laboratory of Hematology, Hôpital Cochin Paris France.
Lower risk (LR) myelodysplastic syndromes (MDS) are heterogeneous hematopoietic stem and progenitor disorders caused by the accumulation of somatic mutations in various genes including epigenetic regulators that may produce convergent DNA methylation patterns driving specific gene expression profiles. The integration of genomic, epigenomic, and transcriptomic profiling has the potential to spotlight distinct LR-MDS categories on the basis of pathophysiological mechanisms. We performed a comprehensive study of somatic mutations and DNA methylation in a large and clinically well-annotated cohort of treatment-naive patients with LR-MDS at diagnosis from the EUMDS registry (ClinicalTrials.
View Article and Find Full Text PDFBone Marrow Transplant
January 2025
Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Research Unit of Key Technique for Diagnosis and Treatments of Hematologic Malignancies, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China; Collaborative Innovation Center of Hematology, Peking University, Beijing, China.
The poor outcome of TP53 alteration has been reported in myelodysplastic syndrome (MDS) patients. However, the role of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in TP53 alteration patients remains debated. Previous studies showed that TP53 mutations had no effect on the prognosis of patients with acute leukemia after haploidentical HSCT (haplo-HSCT).
View Article and Find Full Text PDFAnn Intern Med
January 2025
Center for Hematology and Regenerative Medicine, Department of Medicine Huddinge, Karolinska Institutet, and Department of Hematology, Karolinska University Hospital, Stockholm, Sweden.
Transplant Cell Ther
January 2025
Blood and Marrow Transplant Program, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio. Electronic address:
Background: The relationship between obesity and graft-versus-host disease (GVHD) has been studied in both preclinical and clinical studies with varying results.
Objectives: We aimed to investigate the impact of obesity, as measured by body mass index (BMI), on the incidence, severity, and response to therapy of GVHD in a contemporary cohort.
Study Design: We conducted a retrospective study of patients undergoing allogeneic hematopoietic cell transplant (HCT) for acute myelogenous leukemia and myelodysplastic syndrome between January 2010 and December 2021 at the Cleveland Clinic.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!